UFP Technologies (UFPT) has wrapped up FY 2025 with Q4 revenue of US$148.9 million and basic EPS of US$2.28, framed by trailing twelve month revenue of US$602.8 million and EPS of US$8.87 that reflect earnings growth of 15.8% over the past year. The company has seen revenue move from US$504.4 million and EPS of US$7.69 on a trailing basis in Q4 2024 to US$602.8 million and EPS of US$8.87 by Q4 2025, which sets the scene for investors to weigh solid earnings expansion against a slightly softer 11.3% net margin.

See our full analysis for UFP Technologies.

With the latest results on the table, the next step is to see how these numbers line up with the prevailing narratives about UFP Technologies, and where those stories might need updating.

15.8% earnings growth, but margins slightly thinner at 11.3%

• Over the last 12 months, net income reached US$68.3 million on US$602.8 million of revenue, giving UFP Technologies an 11.3% net margin versus 11.7% a year earlier, while earnings grew 15.8% and have averaged 30.3% per year over five years.
• Bears focus on customer concentration and operational hiccups, yet the current margin profile sits alongside growth that critics say should be harder to sustain:
  • Bears argue that heavy reliance on a few medical customers and labor issues at facilities like AJR could put more pressure on profitability, even though net income has moved from US$59.0 million to US$68.3 million on a trailing basis while margins only slipped 0.4 percentage points.
  • They also point to acquisition integration and higher labor and material costs as threats to margins, which contrasts with the data showing profits still growing faster than revenue, suggesting those headwinds have not erased earnings growth in the last year.

On a year where earnings expanded faster than sales despite a small margin dip, skeptics warn that customer and cost risks could still bite hard in the next downturn, so it is worth reading how the cautious thesis lines up with the numbers in detail. 🐻 UFP Technologies Bear Case

Revenue growth near 5.2% forecasts vs wider US market at 10.4%

• Analysts in this dataset expect UFP Technologies revenue to grow about 5.2% per year, compared with a 10.4% forecast for the broader US market, while they see earnings growing around 13.1% per year thanks to margin assumptions.
• The consensus style view is that operational improvements and MedTech demand can support this gap between slower sales growth and faster earnings growth, but the numbers highlight a trade off:
  • Consensus narrative points to investments in automation, acquisitions and facility expansion as reasons margins could improve from around 11.4% to 13.9% in three years, which is what underpins the 13.1% earnings growth outlook despite only mid single digit revenue growth.
  • At the same time, the same forecasts accept that UFP Technologies may lag the wider US market on top line growth, so the key question for holders is whether margin improvement and mix in higher value medical work can offset that slower revenue trajectory.

P/E of 27.1x and US$336.46 DCF fair value vs US$240.16 share price

• The stock is shown trading on a 27.1x trailing P/E, below the US Medical Equipment industry average of 30.8x and the peer average of 35.2x, and the DCF fair value in this dataset is US$336.46 compared with a current share price of US$240.16, about 28.6% below that DCF estimate.
• Supporters of the bullish narrative see this combination of growth and valuation as attractive, yet the data also sets a high bar for those expectations:
  • On one hand, bullish investors point to historical earnings growth of 15.8% over the last year and about 30.3% per year over five years, arguing that a below peer P/E and a gap to the US$336.46 DCF fair value leave room if those trends continue.
  • On the other hand, the same dataset shows forecast revenue growth of 5.2% per year, which is below the wider US market, so anyone leaning into the bullish case needs to be comfortable that earnings growth and margins can keep doing the heavy lifting even if sales grow more slowly.

If you are weighing that combination of earnings growth, a 27.1x P/E, and a DCF fair value above the current price, it is worth reading how bullish investors connect those dots across MedTech exposure, margins and acquisitions. 🐂 UFP Technologies Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for UFP Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this mix of growth, margins and valuation has you thinking, take a moment to review the numbers yourself and decide how they stack up for you. Then see how our breakdown of 3 key rewards fits with your own view.

See What Else Is Out There

UFP Technologies pairs solid earnings with slower forecast revenue growth than the wider US market and slightly thinner margins, which may limit upside for some investors.

If that mix of modest top line outlook and margin pressure leaves you wanting stronger growth drivers, it could be worth checking our 53 high quality undervalued stocks that already clear tougher value hurdles today.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.